Loading...
•
Mar 31
Acasti Pharma Q4 2025 Earnings Report
Grace Therapeutics reported Q4 2025 results with zero revenue and positive EPS, driven by non-operating income and decreased liabilities.
Key Takeaways
Grace Therapeutics posted a net income for Q4 2025 despite no revenue, mainly due to favorable changes in derivative warrant liabilities and tax benefits. The company highlighted progress on its GTx-104 NDA and secured $15M in funding, supporting its near-term goals.
EPS of $0.10 despite reporting zero revenue in Q4 2025
Net income driven by $3.2M gain from changes in derivative warrant liabilities and $3.2M tax benefit
Company on track to submit NDA for GTx-104 by June 2025
Closed $15M upfront financing with potential for $30M total via warrants
Acasti Pharma
Acasti Pharma
Forward Guidance
Grace Therapeutics expects to submit the NDA for GTx-104 by end of June 2025 and continues to pursue commercialization planning funded by recent private placement.
Positive Outlook
- NDA submission for GTx-104 expected by June 2025
- Phase 3 STRIVE-ON trial met primary endpoint
- Financing provides cash runway into Q3 2026, potentially Q2 2027
- Positive feedback from FDA on NDA preparedness
- Potential additional $15M from warrant exercises
Challenges Ahead
- No revenue generated in Q4 or full year FY2025
- Net loss of $9.6M for FY2025 despite recent cost reductions
- Increase in R&D expenses from continued clinical trials
- Operating loss of $16.7M for FY2025
- Ongoing reliance on financing for operational runway